Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Treatment with radiolabeled somatostatin analogs is a promising tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all 111Indium-, 90Yttrium-, or 177Lutetium-labeled somatostatin analogs used for peptide receptor radionuclide therapy. If kidney protective agents are used, the side-effects are few and mild, and the median duration of the therapy response is 30 and 40 months, respectively. Overall survival is several years from diagnosis. These data compare favorably with the limited number of alternative treatments. If more widespread use of PRRT can be guaranteed, such therapy may become the therapy of first choice.
|Keywords||1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid y 90, Gastroenteropancreatic neuroendocrine tumor, Peptide receptor radionuclide therapy, Somatostatin receptor, Targeted radionuclide therapy, abdominal discomfort, abdominal pain, bone marrow suppression, cancer survival, creatinine clearance, drug dose escalation, drug efficacy, drug megadose, gastropancreatic neuroendocrine tumor, hair loss, hematologic disease, human, leukemia, liver toxicity, multiple cycle treatment, myelodysplastic syndrome, nausea, neuroendocrine tumor, octreotide[3 tyrosine] 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid lu 177, octreotide[3 tyrosine] 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid y 90, overall survival, pancreas tumor, pentetate indium in 111; radioisotope; somatostatin receptor; unclassified drug, priority journal, progression free survival, quality of life, retreatment, review, side effect, single drug dose, survival rate, thrombocytopenia, treatment duration, treatment response, tumor volume, vomiting, yttrium 90|
|Persistent URL||dx.doi.org/10.1016/j.ecl.2010.12.003, hdl.handle.net/1765/23002|
Kwekkeboom, D.J., de Herder, W.W., & Krenning, E.P.. (2011). Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology & Metabolism Clinics of North America, 40(1), 173–185. doi:10.1016/j.ecl.2010.12.003